XML 47 R22.htm IDEA: XBRL DOCUMENT
v3.8.0.1

Employee Benefit Plans | 12 Months Ended
--- | ---
Dec. 31, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract] |
Employee Benefit Plans | Employee Benefit Plans Stock Purchase Plan FIS employees participate in an Employee Stock Purchase Plan (ESPP). Eligible employees may voluntarily purchase, at current market prices, shares of FIS’ common stock through payroll deductions. Pursuant to the ESPP, employees may contribute an amount between 3% and 15% of their base salary and certain commissions. Shares purchased are allocated to employees based upon their contributions. The Company contributes a matching amount as specified in the ESPP of 25% of the employee's contribution. The Company recorded expense of $14 million, $19 million and $26 million, respectively, for the years ended December 31, 2017, 2016 and 2015, relating to the participation of FIS employees in the ESPP. 401(k) Profit Sharing Plans The Company’s U.S. employees are covered by a qualified 401(k) plan. Eligible employees may contribute up to 40% of their pretax annual compensation, up to the amount allowed pursuant to the Internal Revenue Code. The Company generally matches 50% of each dollar of employee contribution up to 6% of the employee’s total eligible compensation. The Company recorded expense of $80 million, $80 million and $38 million, respectively, for the years ended December 31, 2017, 2016 and 2015, relating to the participation of FIS employees in the 401(k) plan. SunGard and its subsidiaries also maintained savings and other defined contribution plans in and outside of the U.S. The U.S. 401(k) plan was frozen with respect to new contributions effective with the SunGard acquisition and during 2016 was merged with the FIS plan, in which legacy SunGard employees now participate. Stock Compensation Plans In 2008, the Company adopted the FIS 2008 Omnibus Incentive Plan ("FIS Plan"). The FIS Plan was amended and restated in 2013 and combined with a plan assumed in conjunction with the 2009 Metavante acquisition ("FIS Restated Plan"). The restatement authorized an additional 6 million shares for issuances, which was approved by stockholders in 2013. In May 2015, another 12 million shares were authorized for issuance under the FIS Restated Plan and approved by stockholders. On November 30, 2015, in conjunction with the SunGard acquisition, the Company registered an additional 10 million shares, representing the remaining shares available for issuance under the SunGard 2005 Management Incentive Plan, as amended ("the SG Plan"), immediately prior to the consummation of the SunGard acquisition. These shares are now available for grant under the FIS Restated Plan for legacy SunGard employees and new FIS employees. Also on November 30, 2015, in conjunction with the SunGard acquisition, the Company registered up to approximately 2 million shares of FIS common stock on a Post-Effective Amendment on Form S-8, reserved for issuance with respect to converted restricted stock units ("RSU's") under the SG Plan. This SG Plan will remain in existence until such time as these RSU's vest and the shares are exercised or the SG Plan is otherwise terminated. A summary of the options granted (all of which vest over three years), outstanding and shares available for grant under the FIS Restated Plan follows (in millions):
| FIS Restated Plan
Available for grant as of December 31, 2015 | 26 |
Granted in 2016 | 5 |
Outstanding as of December 31, 2016 | 17 |
Available for grant as of December 31, 2016 | 21 |
Granted in 2017 | 4 |
Outstanding as of December 31, 2017 | 15 |
Available for grant as of December 31, 2017 | 17 |
The following schedule summarizes the stock option activity for the years ended December 31, 2017, 2016 and 2015 (in millions except for per share amounts):
| Shares |  | Weighted Average Exercise Price
Balance, December 31, 2014 | 15 |  |  | $ | 41.56 |
Granted | 3 |  |  | 65.91 |
Exercised | (2 | ) |  | 29.67 |
Cancelled | — |  |  | 54.08 |
Balance, December 31, 2015 | 16 |  |  | 47.19 |
Granted | 5 |  |  | 63.58 |
Exercised | (3 | ) |  | 36.15 |
Cancelled | (1 | ) |  | 62.25 |
Balance, December 31, 2016 | 17 |  |  | 53.21 |
Granted | 4 |  |  | 80.05 |
Exercised | (5 | ) |  | 44.72 |
Cancelled | (1 | ) |  | 70.50 |
Balance, December 31, 2017 | 15 |  |  | 61.97 |
The intrinsic value of options exercised during the years ended December 31, 2017, 2016 and 2015 was $196 million, $103 million and $73 million, respectively. The Company generally issues shares from treasury stock for stock options exercised. The following table summarizes information related to stock options outstanding and exercisable as of December 31, 2017:
| Outstanding Options |  | Exercisable Options
Range of Exercise Price | Number of Options |  | Weighted Average Remaining Contractual Life |  | Weighted Average Exercise Price |  | Intrinsic Value as of December 31, 2017 (a) |  | Number of Options |  | Weighted Average Remaining Contractual Life |  | Weighted Average Exercise Price |  | Intrinsic Value as of December 31, 2017 (a)
| (In millions) |  |  |  |  |  | (In millions) |  | (In millions) |  |  |  |  |  | (In millions)
$ 0.00 - $ 34.33 | 1 |  |  | 1.40 |  | $ | 30.05 |  |  | $ | 81 |  |  | 1 |  |  | 1.40 |  | $ | 30.05 |  |  | $ | 81 |
$ 34.34 - $ 48.75 | 2 |  |  | 2.76 |  | 48.75 |  |  | 100 |  |  | 2 |  |  | 2.76 |  | 48.75 |  |  | 100 |
$ 48.76 - $ 59.91 | 3 |  |  | 3.81 |  | 58.19 |  |  | 93 |  |  | 2 |  |  | 3.80 |  | 58.17 |  |  | 63 |
$ 59.92 - $ 62.92 | 3 |  |  | 5.21 |  | 62.92 |  |  | 94 |  |  | 1 |  |  | 5.22 |  | 62.92 |  |  | 30 |
$ 62.93 - $ 66.62 | 2 |  |  | 4.71 |  | 65.78 |  |  | 59 |  |  | 1 |  |  | 4.60 |  | 65.52 |  |  | 25 |
$ 66.63 - $ 93.36 | 4 |  |  | 6.14 |  | 80.03 |  |  | 53 |  |  | — |  |  | 3.87 |  | 79.41 |  |  | 1 |
$ 0.00 - $ 93.36 | 15 |  |  | 4.45 |  | 61.97 |  |  | $ | 480 |  |  | 7 |  |  | 3.35 |  | 51.99 |  |  | $ | 300 |
_________________________
(a) | Intrinsic value is based on a closing stock price as of December 31, 2017 of $94.09.
The weighted average fair value of options granted during the years ended December 31, 2017, 2016 and 2015 was estimated to be $12.78, $9.35 and $10.67, respectively, using the Black-Scholes option pricing model with the assumptions below:
| 2017 |  | 2016 |  | 2015
Risk free interest rate | 1.8 | % |  | 1.2 | % |  | 1.4 | %
Volatility | 20.1 | % |  | 20.4 | % |  | 21.7 | %
Dividend yield | 1.4 | % |  | 1.6 | % |  | 1.6 | %
Weighted average expected life (years) | 4.2 |  |  | 4.2 |  |  | 4.2 |
The Company estimates future forfeitures at the time of grant and revises those estimates in subsequent periods if actual forfeitures differ from those estimates. The Company bases the risk-free interest rate that is used in the stock option valuation model on U.S. Treasury securities issued with maturities similar to the expected term of the options. The expected stock volatility factor is determined using historical daily price changes of the Company's common stock over the most recent period commensurate with the expected term of the option and the impact of any expected trends. The dividend yield assumption is based on the current dividend yield at the grant date or management's forecasted expectations. The expected life assumption is determined by calculating the average term from the Company's historical stock option activity and considering the impact of expected future trends. The Company granted a total of 1 million restricted stock shares at prices ranging from $79.44 to $93.36 on various dates in 2017. The Company granted a total of 1 million restricted stock shares at prices ranging from $56.44 to $79.41 on various dates in 2016. The Company granted a total of 1 million restricted stock shares at prices ranging from $61.33 to $69.33 on various dates in 2015. These shares were granted at the closing market price on the date of grant and vest annually over three years. As of December 31, 2017 and 2016, we have approximately 2 million and 3 million unvested restricted shares remaining. The December 31, 2017 balance includes those RSU's converted in connection with the SunGard acquisition as noted above. The Company has provided for total stock compensation expense of $107 million, $137 million and $98 million for the years ended December 31, 2017, 2016 and 2015, respectively, which is included in selling, general, and administrative expense in the Consolidated Statements of Earnings, unless the expense is attributable to a discontinued operation. As of December 31, 2017 and 2016, the total unrecognized compensation cost related to non-vested stock awards is $111 million and $141 million, respectively, which is expected to be recognized in pre-tax income over a weighted average period of 1.5 years and 1.4 years, respectively. German Pension Plans Our German operations have unfunded, defined benefit plan obligations. These obligations relate to benefits to be paid to German employees upon retirement. The accumulated benefit obligation as of December 31, 2017 and 2016, was $57 million and $49 million, respectively, and the projected benefit obligation was $57 million and $50 million, respectively. The plan remains unfunded as of December 31, 2017.

X
- Definition The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -URI http://asc.fasb.org/topic&trid=2228938 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 50 -URI http://asc.fasb.org/subtopic&trid=2208855 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration